VANCOUVER, BC, Feb. 11, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately. Mr. Harlem is the founder and CEO of Altucell Biotech, a cellular engineering and…


Previous articleMindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
Next articleProgressive Doctor Thinks Psychedelics May Be Used to Revive Comatose Patients